Traditional Type 2 Diabetes Drug Attributes Continue to be Key Even as First-Line Treatment Paradigms Shift, According to Findings from Decision Resources Group
May 27, 2014 - Burlington, Mass. –
Decision Resources Group finds that Eli Lilly’s insulin peglispro is set to become the clinical gold-standard in the treatment of patients with type 2 diabetes inadequately controlled with diet and exercise, when metformin is not a therapeutic option. Although metformin continues to dominate the first-line space, a significant proportion of patients are initiated on alternative antidiabetic agents. Experts in the field and recent guidelines indicate that the type 2 diabetes treatment paradigm is shifting towards greater individualization of therapy. This trend represents an increasing opportunity for marketers and drug developers to establish different agents as initial therapies for the treatment of type 2 diabetes. From a selection of current and emerging therapies, insulin peglispro appears to offer the best combination of efficacy, safety, and delivery attributes.
Other key findings from the DecisionBase report entitled Type 2 Diabetes Inadequately Controlled with Diet and Exercise: When Metformin Is Not a Therapeutic Option, What Treatments Hold Greatest Appeal to Physicians and Payers?
Prescribing decisions: Surveyed U.S. and European endocrinologists agree that a therapy’s ability to reduce glycated hemoglobin A1c (HbA1c) is the attribute that most influences their decisions regarding prescribing in type 2 diabetes.
Key unmet need: Greater reductions in body weight was highlighted by endocrinologists as one of the most pertinent unmet needs relating to the treatment of type 2 diabetes and is an issue associated with the use of insulins. Insulin peglispro has the potential to capitalize on this unmet need as it is appears to demonstrate weight neutral or modest weight loss effects.
Factors influencing formulary decisions: Surveyed U.S. payers indicate that improvements in the key efficacy attribute of greater reduction in HbA1c and the key safety attribute of reduced incidence of hypoglycemia will be chief drivers for formulary inclusion.
Comments from Decision Resources Group Analyst Tim Blackstock, M.B. Ch.B., M. Phil.:
“As there are now a multitude of antidiabetic agents and a better understanding of the pathophysiology of the disease and the impact of its complications, physicians face a much more challenging decision about what antidiabetic agents to use and when to use them in their patients.”
“New agents with increased efficacy in reducing HbA1c remain the greatest opportunity for pharmaceutical companies working in the type 2 diabetes therapy market.”
Dr. Blackstock has written a blog on the subject, which can be found here
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.